Vertical Longevity Pharmaceuticals is an Irvine, California biotechnology company founded in 2024 by CEO David Scieszka that develops virus-like particle (VLP) senolytic vaccines designed to train the immune system to clear senescent cells, a hallmark of aging and a driver of chronic disease. Its lead program targets atherosclerosis, the leading cause of death worldwide, with preclinical mouse data showing plaque prevention and restored cardiac function and a PCT patent application covering the platform. The company is preparing non-human primate efficacy studies with academic collaborators including Wake Forest University, funded through a NetCapital community offering and an accredited-investor tranche.
1
Round
1
Industry
4
Tags
Sep 28, 2026
Latest raise
Funding activity · 1 round
Sep 28, 2026
$110,000
Seed
Article coming soon.
Pricing
Public hubs orient you on the raise. Paid plans unlock live AI adoption signals across your market.
For individuals and small teams getting started with AI buyer intelligence.
$149
/month
Features
For outbound teams and agencies that need more coverage and faster signal cadence.
$249
/month
Features
Act on this raise
Funding is the starting point. VeilStrat shows whether capital is showing up as hiring, tools, and web activity you can sell into.
